News Sentiment

MBRX sentiment intelligence

Moleculin Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.10 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-7.9% over one week, -27.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -7.9% Price reacting lower
Trend fit Trend inactive -27.1% over four weeks
Fair value -97.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
GlobeNewswire 8
Market source 7
Stock Titan 5
Moomoo 4
Investing.com 4
Stocktwits 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Earnings 28
Market update 25
Analyst action 3
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
TradingView Direct company coverage

Price to sales forward of Moleculin Biotech, Inc. – GETTEX:MOL0

This article provides the "Price to sales forward" metric for Moleculin Biotech, Inc. (MOL0) on the GETTEX exchange. The content is primarily a data point embedded within a larger financial platform, indicating a value of "No trades" for the specified period.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 07:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Moleculin Biotech, Inc. – GETTEX:MOL0

This article displays the "Enterprise value to revenue forward" metric for Moleculin Biotech, Inc. (GETTEX:MOL0). The main content consists of the company name, stock ticker, and the specific financial metric. The article is from TradingView and indicates a market-closed status f

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 22:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0

This article displays the "Price to book forward" for Moleculin Biotech, Inc. (GETTEX:MOL0). It presents a data point under the "Financials" section for a specific period, detailing its value and change percentages. The content is presented within the TradingView platform, focusi

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 19:39
Source
TradingView
Stocktwits Direct company coverage

Why Did MBRX Stock Climb 14% Today?

Moleculin Biotech's stock (MBRX) surged 14% after the company announced it is on track to treat the 45th patient in its Miracle study for Annamycin by Q1 2026. The drug is being investigated for acute myeloid leukemia, with preliminary data showing a 40% complete remission rate i

Tone
Positive 72/100
Event
Market update
Published
11 Jul 2026 18:40
Source
Stocktwits
TradingView Direct company coverage

Enterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRX

This article provides financial data for Moleculin Biotech, Inc. (NASDAQ: MBRX), specifically focusing on its enterprise value to EBITDA forward. The content is presented within the TradingView platform, detailing financial metrics, market information, and company background for

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 06:45
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H

This article displays the "Price to earnings forward" metric for Moleculin Biotech, Inc. (LSE:0K2H) on the TradingView platform. The content primarily shows navigation elements and structural information from the platform, indicating where this financial data would be presented.

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 00:41
Source
TradingView
GlobeNewswire Direct company coverage

Moleculin CEO, Walter Klemp, Highlights Positive

Moleculin's CEO, Walter Klemp, discussed positive preliminary results from the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) during a Virtual Investor "What This Means" segment. He highlighted early efficacy trends, summarized key data, an

Tone
Positive 75/100
Event
Earnings
Published
07 Jul 2026 05:45
Source
GlobeNewswire
Sahm Direct company coverage

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

Moleculin Biotech, Inc. CEO, Walter Klemp, discussed positive preliminary efficacy results from the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) during a Virtual Investor "What This Means" segment. He highlighted the significance of early

Tone
Positive 80/100
Event
Earnings
Published
06 Jul 2026 15:33
Source
Sahm
The Manila Times Direct company coverage

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment

Moleculin Biotech, Inc. CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). He provided insights into ear

Tone
Positive 73/100
Event
Earnings
Published
06 Jul 2026 13:09
Source
The Manila Times
Quiver Quantitative Direct company coverage

Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment

Moleculin Biotech's CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in the pivotal Phase 2/3 MIRACLE trial for Annamycin, a treatment for relapsed or refractory acute myeloid leukemia (R/R AML). While the preliminary data sh

Tone
Positive 60/100
Event
Earnings
Published
06 Jul 2026 12:44
Source
Quiver Quantitative
Stock Titan Direct company coverage

Moleculin says early MIRACLE trial data support Annamycin in leukemia

Moleculin CEO Walter Klemp discussed positive preliminary efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). The discussion highlighted early efficacy trends across

Tone
Negative 35/100
Event
Earnings
Published
06 Jul 2026 12:41
Source
Stock Titan
Moomoo Direct company coverage

Moleculin Biotech | 8-K: Current report

This document is an 8-K filing by Moleculin Biotech, indicating a current report with the SEC. It likely contains information on significant events or changes within the company that shareholders should be aware of.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 05:09
Source
Moomoo
Finviz Direct company coverage

MBRX - Moleculin Biotech Inc Dividends

This article provides comprehensive financial data for Moleculin Biotech Inc (MBRX), including its last close price, market capitalization, income, sales, key financial ratios, and performance metrics. It details the company's dividend estimates, earnings per share, insider and i

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 13:10
Source
Finviz
Stock Titan Direct company coverage

Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim

Moleculin Biotech (MBRX) reported positive interim results from its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML), showing Annamycin achieved significantly higher remission rates compared to the control arm after a single treatment cycle.

Tone
Positive 74/100
Event
Earnings
Published
02 Jul 2026 20:10
Source
Stock Titan
Investing.com Direct company coverage

Moleculin reports positive interim data from AML trial

Moleculin Biotech, Inc. announced positive interim data from the first 45 patients in Part A of its Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia, causing its stock to surge. The trial's experimental Annamycin arms showed higher complete remission rate

Tone
Positive 76/100
Event
Market update
Published
01 Jul 2026 03:39
Source
Investing.com
TradingView Direct company coverage

Moleculin Biotech, Inc. Financial Disclosures & Filings

This page provides an extensive list of Moleculin Biotech, Inc.'s financial disclosures and regulatory filings, including earnings reports, corporate presentations, and study updates from 2022 to 2026. The documents offer insights into the company's performance, strategy, and adv

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 02:32
Source
TradingView
Stocktwits Direct company coverage

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Shares of Moleculin Biotech (MBRX) plunged over 25% after interim data from its Annamycin clinical trial for acute myeloid leukemia did not achieve statistical significance, despite showing a trend favoring the drug. The company emphasized that more data from additional patients

Tone
Negative 13/100
Event
Market update
Published
30 Jun 2026 18:52
Source
Stocktwits
Bitget Direct company coverage

Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data.

Moleculin Biotech, Inc. (Moleculin) has announced positive interim analysis results from its phase 2/3 "Miracle" clinical trial. The core candidate drug, Annamycin, demonstrated significantly superior efficacy in inducing complete remission for acute myeloid leukemia, achieving a

Tone
Positive 94/100
Event
Earnings
Published
30 Jun 2026 14:40
Source
Bitget
Minichart Direct company coverage

Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates

Moleculin Biotech, Inc. has released an investor presentation and provided key regulatory updates. The company received approximately $2.7 million from warrant exercises, increasing its outstanding shares to 7,065,000. These updates are intended to inform investors about the comp

Tone
Positive 67/100
Event
Regulatory and legal
Published
30 Jun 2026 13:02
Source
Minichart
StreetInsider Direct company coverage

Form 8-K Moleculin Biotech, Inc. For: Jun 30

Moleculin Biotech, Inc. filed a Form 8-K announcing positive preliminary unblinded efficacy results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin. The study, analyzing 45 patients with relapsed or refractory acute myeloid leukemia (R/R AML), showed favorable ef

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 12:39
Source
StreetInsider
GlobeNewswire Direct company coverage

Moleculin Reports Positive Phase 2/3 MIRACLE Interim

Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the

Tone
Positive 73/100
Event
Earnings
Published
30 Jun 2026 12:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised

Moleculin Biotech (NASDAQ: MBRX) has reported raising approximately $2.7 million from the exercise of warrants covering 1.36 million shares of common stock. Following these exercises, the company now has 7,065,000 shares of common stock outstanding as of June 29, 2026. Moleculin

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 12:11
Source
Stock Titan
TradingView Direct company coverage

Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)

This article provides an overview of Moleculin Biotech, Inc. (NASDAQ: MBRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It details recent earnings, revenue, net income, and market capitalization, while also answering frequent

Tone
Negative 29/100
Event
Earnings
Published
29 Jun 2026 09:11
Source
TradingView
Market source Direct company coverage

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML). Both Annamycin treatment arms demonstrated significantly high

Tone
Positive 71/100
Event
Earnings
Published
28 Jun 2026 09:09
Source
Market source
TradingView Direct company coverage

MBRX Forecast — Price Target — Prediction for 2027

This article provides a stock forecast for Moleculin Biotech, Inc. (MBRX), including analyst price targets, historical performance, and key financial data. It notes that analysts predict a maximum price of $22.00 and a minimum of $10.00 for MBRX. The company's current stock price

Tone
Negative 38/100
Event
Analyst action
Published
27 Jun 2026 03:40
Source
TradingView